
Better fight against hepatitis E
Neutralising antibodies can prevent severe courses
Read moreTWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
Registration for the Lower Saxony International Summer Academy 2025 is open until 2025.
Find more information here!
Neutralising antibodies can prevent severe courses
Read moreNews from the RESIST Cluster of Excellence
Read moreResearch team from Hannover adapts hepatitis C virus to infect mouse liver cells
Read moreWe conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Bartsch Y, Webb N, Burgess E, Kang J, Lauffenburger D, Julg B
van der Sluis R, García-Rodríguez J, Nielsen I, Gris-Oliver A, Becker J, Costa B, Chaudhry M, Werner M, Laustsen A, Pedersen J, Gammelgaard K, Mogensen T, Kalinke U, Cicin-Sain L, Bak R, Kristensen L, Jakobsen M
Goranovič D, Jenko B, Ramšak B, Podgoršek Berke A, Bedrač L, Horvat J, Šala M, Makuc D, Carriche G, Silva L, Lopez Krol A, Pšeničnik A, Durán Alonso M, Avbelj M, Stavber S, Plavec J, Sparwasser T, Müller R, Kosec G, Fujs Š, Petković H
The project is developing methods to specifically transport antibiotics into cells such as alveolar macrophages, which are important in Mycobacterium tuberculosis infections. The aim is to overcome resistance and reduce side effects.
In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.
The CoViPa consortium uses computer-assisted high-throughput virus discovery and evolutionary analyses to identify RNA viruses with high spillover risk and potential animal host reservoirs and to investigate new pathogenicity factors.